Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Reserpine

FDA-approved product (elixir, oral), marketed as Hiserpia, Rau-Sed, Reserpine and 6 more.

Registered studies
10
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Reserpine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Rauwolfia alkaloids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Reserpine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Reserpine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy

    NCT06199778 · start 2022-06-01

    Registered record
    Registry ID
    NCT06199778
    Conditions
    Traumatic Brain Injury
    Interventions
    Rehabilitation therapy; Intermittent Oro-esophageal Tube Feeding; Nasogastric tube feeding; Reserpine; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2022-06-01
    Completion
    2023-06-15
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury
    InterventionRehabilitation therapy; Intermittent Oro-esophageal Tube Feeding; Nasogastric tube feeding; Reserpine +1 more
    PhaseNot applicable
    Registry statusTerminated

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

    NCT02684786 · start 2016-07

    Registered record
    Registry ID
    NCT02684786
    Conditions
    Pulmonary Artery Hypertension
    Interventions
    reserpine; stellate ganglion block; lidocaine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2016-07
    Completion
    2016-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Artery Hypertension
    Interventionreserpine; stellate ganglion block; lidocaine
    PhasePhase 1
    Registry statusWithdrawn

  • Mechanisms of Refractory Hypertension (Reserpine)

    NCT03223272 · start 2015-07-23

    Registered record
    Registry ID
    NCT03223272
    Conditions
    Refractory Hypertension
    Interventions
    Reserpine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07-23
    Completion
    2020-01-31
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Hypertension
    InterventionReserpine
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

    NCT00267657 · start 2004-01

    Registered record
    Registry ID
    NCT00267657
    Conditions
    Amphetamine-Related Disorders
    Interventions
    Reserpine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2004-01
    Completion
    2004-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmphetamine-Related Disorders
    InterventionReserpine
    PhasePhase 1
    Registry statusUnknown

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted

  • Reserpine for the Treatment of Cocaine Dependence - 1

    NCT00033033 · start 2001-07

    Registered record
    Registry ID
    NCT00033033
    Conditions
    Cocaine-Related Disorders; Substance-Related Disorders
    Interventions
    Reserpine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    2003-05
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders; Substance-Related Disorders
    InterventionReserpine
    PhasePhase 2
    Registry statusCompleted

  • Action to Control Cardiovascular Risk in Diabetes (ACCORD)

    NCT00000620 · start 1999-09

    Registered record
    Registry ID
    NCT00000620
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus, Type 2; Diabetes Mellitus; Coronary Disease
    Interventions
    Anti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-09
    Completion
    2012-12
    Enrolment
    10,251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension +3 more
    InterventionAnti-hyperglycemic Agents; Anti-hypertensive Agents; Blinded fenofibrate or placebo plus simvastatin
    PhasePhase 3
    Registry statusCompleted

  • Systolic Hypertension in the Elderly Program (SHEP)

    NCT00000514 · start 1984-06

    Registered record
    Registry ID
    NCT00000514
    Conditions
    Cardiovascular Diseases; Cerebrovascular Disorders; Heart Diseases; Hypertension
    Interventions
    chlorthalidone; atenolol; reserpine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1984-06
    Completion
    1996-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Cerebrovascular Disorders; Heart Diseases; Hypertension
    Interventionchlorthalidone; atenolol; reserpine
    PhasePhase 3
    Registry statusCompleted

  • Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

    NCT00000499 · start 1980-09

    Registered record
    Registry ID
    NCT00000499
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    chlorthalidone; reserpine; hydralazine; metoprolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1980-09
    Completion
    1983-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventionchlorthalidone; reserpine; hydralazine; metoprolol
    PhasePhase 2
    Registry statusCompleted